Contrarian Corpus
activist research note initial thesis
2026-04-01 · 20 pages

Welltower Inc. WELL

Welltower's 10-year executive program could pay CEO Mitra up to $3 billion while incentivizing dilutive growth at a 144% NAV premium — shareholders should sell WELL and rotate into Ventas or AHR.

N 5 Narrative
V 4 Visual
C 4 Craft
Source URL unavailable

Thesis

Land & Buildings argues Welltower's Ten-Year Executive Continuity and Alignment Program, adopted by the Board in October 2025 without a binding shareholder vote, is the most egregious REIT compensation structure in history. CEO Shankh Mitra — in the job just 5.5 years — could receive up to $3.04 billion at a $350 share-price cap, plus $110–240 million in tax-advantaged distributions, dwarfing David Simon's $120M retention award (killed by a 73% shareholder vote in 2014) and Hamid Moghadam's self-imposed $25M annual cap at Prologis. Termination provisions trigger roughly $500M+ acceleration if Mitra is fired for poor performance, creating a structural trap. With WELL trading at a historic 144% premium to Green Street NAV and 33x forward FFO, L&B recommends shareholders sell WELL and rotate into Ventas or American Healthcare REIT for ~50% more NAV per dollar invested.

SCQA

Situation

Welltower is a senior housing REIT whose Board adopted a Ten-Year Executive Continuity and Alignment Program for CEO Shankh Mitra in October 2025 without a binding shareholder vote, wrapped in rhetoric of sacrifice and alignment.

Complication

The plan could pay Mitra up to $3.04 billion — 10 to 25 times the largest prior REIT comp package — with systematically easy performance hurdles, misleading $110K salary framing, a fee peer group padded with non-REITs, and termination provisions that trap the Board from firing him.

Resolution

Shareholders should sell Welltower stock and reallocate into Ventas (VTR) or American Healthcare REIT (AHR), which offer comparable senior housing exposure at substantially lower valuations without the compensation-driven growth incentives.

Reward

Switching from WELL to VTR or AHR delivers approximately 50% more net asset value per dollar invested, higher dividend yields, and avoids a ~60% downside risk if WELL reverts to Green Street NAV or a 30% decline even to 2023 premium levels.

The three reasons

  1. 1

    CEO Mitra's potential $3.04B payout dwarfs any REIT CEO compensation in history

  2. 2

    Termination provisions trigger ~$500M+ acceleration — Board cannot fire CEO without enriching him

  3. 3

    WELL trades at 144% NAV premium and 33x FFO; VTR/AHR offer ~50% more NAV per dollar

Primary demands

  • Sell Welltower shares and reallocate to Ventas (VTR) or American Healthcare REIT (AHR)
  • Vote against say-on-pay at the May 2026 annual meeting
  • Board should rescind or restructure the 10-Year Executive Continuity and Alignment Program
  • Impose rigorous performance hurdles and a binding shareholder vote on mega-grants

KPIs cited

CEO max LTIP payout
~$3.04 billion at $350/share cap, plus $110–240M cumulative tax-advantaged distributions
Premium to Green Street NAV
144% — highest in Company history; compared to 22–36% YE2020–YE2022
Forward FFO multiple
33x vs. 5-year average of 25x
Termination without-cause acceleration
~$500M+ in immediate LTIP unit vesting
Time-based LTIP units
2,485,146 units worth $524M at $210 / $870M at $350 — no performance required
2023 say-on-pay support
52% — lowest in Company history, down from ≥93% through 2022
Comp Committee meetings in 2025
25 meetings — ~5x typical REIT comp committee frequency
Equity issuance in 2025
56.1 million shares / $8.9 billion in gross proceeds
Performance-based % of LTIP
50% vs. 75% at SPG and 100% at PLD
Passive index ownership
Vanguard/BlackRock/State Street together own ~30% of WELL
Since-plan total return gap
VTR +21% vs. WELL +16% since October 27, 2025 (440 bps)
Mitra tenure vs. payout comparison
5.5 years as CEO; Simon 31 years, peak annual $61.4M; Moghadam 13 years, peak $50.9M

Pattern membership

Where this document fits across the library's 12 rhetorical / structural patterns.

Precedents cited

  • David Simon / Simon Property Group $120M retention award (killed by 73% shareholder vote 2011-2014)
  • Hamid Moghadam / Prologis voluntary $25M annual comp cap (2024)
  • Prologis Outperformance Plan (POP) — 2022–2024 cycle paid zero
  • Alexandria Real Estate (ARE) — life science REIT whose stock fell ~80% from 2021 peak
  • Tornetta v. Musk (Delaware Chancery, 2024)
  • In re Investors Bancorp (Delaware Supreme Court, 2017)
  • Trade Desk (Delaware Supreme Court, November 2025)
  • Glass Lewis 2023 mega-grant policy

Notable slides (6)

Notes

White paper / research note format signed by Jonathan Litt (L&B). L&B explicitly discloses a short position in WELL and long positions in VTR and AHR, but does not disclose an ownership percentage. Unusual for L&B (typically long-activist): the closing ask is not a proxy fight or board seat but an exit recommendation — effectively a public short thesis framed around governance. Heavy use of CEO quote contradictions (the '$110K salary' narrative, 'paranoid about success' Q2 2025 quote, 'biggest capital allocation mistake' Holiday by Atria self-admission). Strong comparative tables (SPG/PLD/WELL comp scorecard, share-price-to-payout matrix, Alexandria timeline of destruction). Branded editorial design with consistent blue/grey palette and section dividers. Campaign is nascent — first public thesis against this specific October 2025 plan ahead of May 2026 say-on-pay vote.